title: Talnetant GlaxoSmithKline.
abstract: Talnetant (SB-223412) is a selective, orally active NK3 antagonist based on 4-quinolinecarboxamide, and is under development by GlaxoSmithKline (formerly SmithKline Beecham) for the potential treatment of several disorders, including urinary incontinence, irritable bowel syndrome and schizophrenia. By November 2004, the compound had completed phase II trials.
authors.affiliation: Menarini Ricerche SpA, Via Sette Santi 1, 50131, Firenze, Italy. sevangelista@menarini-recherche.it
authors.forename: Stefano
authors.initials: S
authors.lastname: Evangelista
mesh_terms: D000818:Animals; D017322:Clinical Trials, Phase II as Topic; D006801:Humans; D043183:Irritable Bowel Syndrome / Q000188:drug therapy; D015394:Molecular Structure; D011804:Quinolines / Q000737:chemistry / Q000494:pharmacology / Q000627:therapeutic use*; D018039:Receptors, Tachykinin / Q000037:antagonists & inhibitors* / Q000502:physiology; D012559:Schizophrenia / Q000188:drug therapy; D016896:Treatment Outcome; D014549:Urinary Incontinence / Q000188:drug therapy
chemical_list: D011804:Quinolines; D018039:Receptors, Tachykinin; C106716:SB 223412